- Home
- SEPN
SEPN
SEPTERNA INC
as 11-15-2024 4:00pm EST
Stocks
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR.
| Founded: | 2022 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 1.0B | IPO Year: | 2024 |
| Target Price: | N/A | AVG Volume (30 days): | 399.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.75 | EPS Growth: | N/A |
| 52 Week Low/High: | $18.62 - $26.34 | Next Earning Date: | 11-26-2024 |
| Revenue: | $838,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest SEPTERNA INC News
SEPN Breaking Stock News: Dive into SEPN Ticker-Specific Updates for Smart Investing
GlobeNewswire
18 days ago
Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering
Argus Research
18 days ago
Daily – Vickers Top Buyers & Sellers for 10/30/2024
Argus Research
19 days ago
Daily – Vickers Top Buyers & Sellers for 10/29/2024
GlobeNewswire
23 days ago
Septerna Prices Upsized Initial Public Offering
Compare SEPN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SEPN SEPTERNA INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.